Improving assessment of prostate cancer bone metastases using advanced diffusion imaging

项目摘要 转移性前列腺癌(PCA)是一种使人衰弱的疾病，通常是致命的，影响着数万人。 在美国和世界各地的男性。存在有效的治疗选择来缓解症状和控制 癌症，还有其他的正在进行检测。甚至有人认为，如果我们能做到这一点，有些病人可能会被治愈。 当转移性疾病仅限于少数部位时，就可以发现它。然而，无论是治疗还是 新疗法的测试需要对转移瘤进行准确的成像。不幸的是，大多数前列腺癌转移 在骨骼中，成像质量很差，转移被认为是常规检查无法测量的。 技巧。该项目的广泛目标是优化和测试量化的创新方法 前列腺癌的成像、辐射靶向和反应评估。该提案的核心是扭曲校正 和先进的扩散磁共振成像模型，这些模型对于检测PCA病变是有效的，并已显示 与临床结果相关的前景看好。 该提案的第一个具体目标是将失真校正的扩散磁共振技术应用于 放射治疗计划系统及测量失真校正对精确度的影响 骨转移瘤的准确勾画。第二个目标是评估扩散的预后价值。 MRI指标作为骨转移瘤放射治疗后临床结果的预测指标 一些少转移瘤患者的生存受益的证据，以及对患者生活质量的重要影响 疼痛的骨头损伤。第三个目的是评估磁共振弥散成像用于定量治疗的可靠性。 个体骨转移的反应评估，临床实践和临床试验尚未满足的需求。 Seibert博士，放射医学和生物工程助理教授，寻求促进患者 关注这一提议，并提高其他研究人员更有效地测试实验的能力 前列腺癌的治疗。同时，塞伯特博士将获得作为首席研究员的指导经验，并 以他的工程、临床和成像背景为基础，在开发方面具有特定的专业知识 主成分分析评估的量化工具。加州大学圣地亚哥分校和多模式成像和遗传学中心- 在K08提案导师的指导下，戴尔博士-为这个项目和职业生涯提供理想的环境 发展，有一支经验丰富的导师团队和丰富的资源和熟练的人才来促进 成功完成具体目标，并在#年开始Seibert博士的内科科学家生涯 放射肿瘤学和生物医学成像。

Project Summary Metastatic prostate cancer (PCa) is a debilitating and often deadly disease affecting tens of thousands of men in the U.S. and worldwide. Effective therapeutic options exist for symptom relief and control of the cancer, with others in the pipeline for testing. It is even thought that some patients might be cured if we could detect metastatic disease when it is limited to only a small number of locations. However, both treatment and testing of novel therapies require accurate imaging of the metastases. Unfortunately, most PCa metastases are in bones, where imaging quality is poor, and metastases are considered unmeasurable with conventional techniques. The broad goal of this project is to optimize and test innovative approaches to quantitative imaging, radiation targeting, and response assessment of PCa. The proposal centers on distortion correction and advanced diffusion MRI models, which are effective for detection of PCa lesions and have shown promising association with clinical outcomes. The first specific aim of the proposal is to implement distortion-corrected diffusion MRI into a radiotherapy treatment planning system and measure the impact of distortion correction on precise and accurate tumor delineation in bone metastases. The second aim is to evaluate the prognostic value of diffusion MRI metrics as predictors of clinical outcomes after radiotherapy for bone metastases, a treatment with evidence of a survival benefit in some oligometastatic patients and important for quality of life in patients with painful bone lesions. The third aim is to evaluate the reliability of diffusion MRI for quantitative treatment response assessment of individual bone metastases, an unmet need for clinical practice and clinical trials. Dr. Seibert, assistant professor of Radiation Medicine and Bioengineering, seeks to advance patient care with this proposal and to improve the ability of other investigators to more efficiently test experimental treatments for PCa. Simultaneously, Dr. Seibert will gain mentored experience as a principal investigator and build on his engineering, clinical, and imaging backgrounds with specific expertise in the development of quantitative tools for PCa assessment. UC San Diego and the Center for Multimodal Imaging and Genetics— directed by K08 proposal mentor, Dr. Dale—provide the ideal environment for this project and career development, with a veteran team of mentors and an abundance of resources and skilled personnel to facilitate successful completion of the specific aims and to launch Dr. Seibert’s career as a physician-scientist in radiation oncology and biomedical imaging.